CBD offers hope for kids with Hard-to-Treat seizures
NCT ID NCT02556008
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study gives cannabidiol (CBD) to 25 children aged 1 to 17 with severe epilepsy that hasn't improved with other treatments. The goal is to see if CBD can reduce seizure frequency. Children will be monitored before and after starting CBD, which is added to their current epilepsy medications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cannabidiol (CBD)
- What this could lead to
- If it works, this could provide a treatment option for children with severe epilepsy who have not been helped by other medications.
- What could go wrong
- This is an early, small study with only 25 children, and CBD is not yet FDA-approved. It may not work for everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 17 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age criteria between the ages of 1 and 17 years. 2. Documentation of a diagnosis of drug resistant epilepsy as evidenced by failure to control seizures despite appropriate trial of two or more AEDs at therapeutic doses. Documentation must include the diagnosis of epilepsy type or epilepsy syndrome, as well as the underlying cause, when known. 3. Between 1-3 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment. Vagus nerve stimulator (VNS), ketogenic diet and modified Atkins diet do not count toward this limit. 4. VNS must be on stable settings for a minimum of 3 months. 5. If on ketogenic diet, must be on stable ratio for a minimum of 3 months 6. Written informed consent obtained from the patient or the patient's legal representative must be obtained prior to beginning treatment. Exclusion Criteria: 1. Use of any "community acquired" cannabidiol product over the last 3 months. 2. Use of any investigational treatments over the last 3 months. 3. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete entire study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Refractory childhood epilepsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, Los Angeles
Los Angeles, California, 90095, United States